For help on how to get the results you want, see our search tips.
566 results
Categories
Human Remove Human filter
Medicine type
Exceptional circumstances Remove Exceptional circumstances filter
Conditional approval Remove Conditional approval filter
Additional monitoring Remove Additional monitoring filter
Generic Remove Generic filter
Medicine
Direct healthcare professional communication Remove Direct healthcare professional communication filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Summaries of opinion Remove Summaries of opinion filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Veyvondi (updated)
vonicog alfa, von Willebrand Diseases
Date of authorisation: 31/08/2018,, Revision: 8, Authorised, Last updated: 19/09/2023
-
List item
Human medicine European public assessment report (EPAR): Litfulo (updated)
ritlecitinib tosilate, Alopecia Areata
Date of authorisation: 15/09/2023,, Authorised, Last updated: 18/09/2023
-
List item
Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) (updated)
Chenodeoxycholic acid, Xanthomatosis, Cerebrotendinous; Metabolism, Inborn Errors
Date of authorisation: 10/04/2017,,
,
, Revision: 6, Authorised, Last updated: 18/09/2023
-
List item
Human medicine European public assessment report (EPAR): Jinarc (updated)
Tolvaptan, Polycystic Kidney, Autosomal Dominant
Date of authorisation: 27/05/2015,, Revision: 20, Authorised, Last updated: 18/09/2023
-
List item
Human medicine European public assessment report (EPAR): GHRYVELIN (previously Macimorelin Aeterna Zentaris) (updated)
macimorelin acetate, Diagnostic Techniques, Endocrine
Date of authorisation: 11/01/2019,, Revision: 3, Authorised, Last updated: 18/09/2023
-
List item
Human medicine European public assessment report (EPAR): Ranivisio (updated)
ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 25/08/2022,,
, Revision: 3, Authorised, Last updated: 18/09/2023
-
List item
Human medicine European public assessment report (EPAR): Mepsevii (updated)
vestronidase alfa, Mucopolysaccharidosis VII
Date of authorisation: 23/08/2018,,
,
, Revision: 7, Authorised, Last updated: 14/09/2023
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Accord (updated)
docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms
Date of authorisation: 22/05/2012,, Revision: 17, Authorised, Last updated: 14/09/2023
-
List item
Human medicine European public assessment report (EPAR): Deferasirox Accord (updated)
deferasirox, Iron Overload; beta-Thalassemia
Date of authorisation: 09/01/2020,, Revision: 5, Authorised, Last updated: 14/09/2023
-
List item
Human medicine European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius) (updated)
carmustine, Hodgkin Disease; Lymphoma, Non-Hodgkin
Date of authorisation: 18/07/2018,, Revision: 8, Authorised, Last updated: 14/09/2023
-
List item
Human medicine European public assessment report (EPAR): Lacosamide Adroiq (updated)
lacosamide, Epilepsy
Date of authorisation: 31/05/2023,, Revision: 1, Authorised, Last updated: 14/09/2023
-
List item
Human medicine European public assessment report (EPAR): Neparvis (updated)
sacubitril, valsartan, Heart Failure
Date of authorisation: 26/05/2016,, Revision: 18, Authorised, Last updated: 13/09/2023
-
List item
Human medicine European public assessment report (EPAR): Xevudy (updated)
Sotrovimab, COVID-19 virus infection
Date of authorisation: 17/12/2021,, Revision: 9, Authorised, Last updated: 13/09/2023
-
List item
Human medicine European public assessment report (EPAR): Beovu (updated)
brolucizumab, Wet Macular Degeneration
Date of authorisation: 13/02/2020,, Revision: 10, Authorised, Last updated: 13/09/2023
-
List item
Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene) (updated)
Pomalidomide, Multiple Myeloma
Date of authorisation: 05/08/2013,, Revision: 24, Authorised, Last updated: 13/09/2023
-
List item
Human medicine European public assessment report (EPAR): Mektovi (updated)
binimetinib, Melanoma
Date of authorisation: 20/09/2018,, Revision: 7, Authorised, Last updated: 12/09/2023
-
List item
Human medicine European public assessment report (EPAR): Roctavian (updated)
valoctocogene roxaparvovec,
Date of authorisation: 24/08/2022,,
,
, Revision: 3, Authorised, Last updated: 12/09/2023
-
List item
Human medicine European public assessment report (EPAR): Pemazyre (updated)
pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021,,
,
, Revision: 6, Authorised, Last updated: 12/09/2023
-
List item
Human medicine European public assessment report (EPAR): Vegzelma (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022,,
, Revision: 4, Authorised, Last updated: 12/09/2023
-
List item
Human medicine European public assessment report (EPAR): Abiraterone Mylan (updated)
abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 20/08/2021,, Revision: 4, Authorised, Last updated: 11/09/2023
-
List item
Human medicine European public assessment report (EPAR): Comirnaty (updated)
Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020,,
, Revision: 44, Authorised, Last updated: 11/09/2023
-
List item
Human medicine European public assessment report (EPAR): Tremelimumab AstraZeneca (updated)
Tremelimumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/02/2023,, Revision: 1, Authorised, Last updated: 11/09/2023
-
List item
Human medicine European public assessment report (EPAR): Benlysta (updated)
belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011,, Revision: 31, Authorised, Last updated: 11/09/2023
-
List item
Human medicine European public assessment report (EPAR): Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) (updated)
aripiprazole, Schizophrenia; Bipolar Disorder
Date of authorisation: 30/06/2015,, Revision: 16, Authorised, Last updated: 08/09/2023
-
List item
Human medicine European public assessment report (EPAR): Dimethyl fumarate Mylan (updated)
dimethyl fumarate, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/05/2022,, Revision: 4, Authorised, Last updated: 08/09/2023